Business Context and Reporting Period
Company: DexCom, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: DexCom is a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes management. Key products include the G7 and G7 15 Day systems, the G6 system (transitioning to G7 by end of 2026), and Stelo, an over-the-counter biosensor launched in August 2024. The company operates manufacturing facilities in the U.S., Malaysia, and is constructing a new facility in Ireland.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $4,662.0 | $4,033.0 | +16% |
| Gross Profit | $2,801.9 | $2,438.2 | +15% |
| Gross Margin | 60.1% | 60.5% | -40 bps |
| Operating Income | $911.8 | $600.0 | +52% |
| Net Income | $836.3 | $576.2 | +45% |
| Diluted EPS | $2.09 | $1.42 | +47% |
| Operating Cash Flow | $1,440.7 | $989.5 | +46% |
| Cash & Equivalents | $2,000.0 | $2,580.0 | -$580.0 |
| Debt (Convertible Notes) | $1,250.0 | $2,457.5 | -$1,207.5 |
Note: Debt decreased due to the maturity and repayment of $1.21 billion in 2025 Notes in November 2025. Remaining debt consists of $1.25 billion in 2028 Notes.
Material Changes vs. Prior Period
- Revenue Growth: Driven by the addition of approximately 600,000–700,000 net customers (excluding Stelo) and increased sales volume of disposable sensors. Growth was partially offset by pricing headwinds from rebates and channel mix.
- Margin Compression: Gross margin decreased slightly to 60.1% from 60.5% due to manufacturing inefficiencies, lower production yields, and total replacement costs associated with ensuring supply availability.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses remained relatively flat ($1,291.0M vs $1,285.8M) despite higher compensation and software costs, due to an $87.2M reduction in legal expenses following the settlement of a patent infringement lawsuit with Abbott in December 2024.
- Debt Reduction: Significant reduction in total debt following the full cash repayment of the 2025 Notes at maturity.
- Share Repurchases: The company repurchased 7.7 million shares for $500.0 million under the 2025 Share Repurchase Program.
Outlook, Risks, and Management Commentary
Management Commentary & Guidance
Management expects continued growth driven by the G7 and G7 15 Day systems and the expansion of Stelo. The company anticipates transitioning G6 customers to G7 systems by the end of 2026. Capital expenditures are expected to remain significant to support the build-out of manufacturing facilities in Ireland and Malaysia.
Key Risks and Contingencies
- Regulatory Action: In March 2025, DexCom received an FDA warning letter regarding non-conformities in manufacturing processes and quality management systems at its San Diego and Mesa facilities. While not currently restricting production, failure to resolve these issues could lead to product recalls or production shutdowns.
- Reimbursement Pressure: CMS extended the DMEPOS competitive bidding program to include CGMs, with contracting beginning in 2027 and payment changes effective January 1, 2028. This is expected to result in lower Medicare reimbursement rates.
- Legal Proceedings: The company faces multiple securities class actions regarding revenue guidance and device accuracy, as well as product liability class actions alleging G6/G7 devices were adulterated or misbranded. Outcomes are uncertain and could materially impact financial results.
- Supply Chain: Reliance on single-source suppliers for critical components (e.g., ASICs, polymers) creates vulnerability to supply disruptions.
Investor Verification Checklist
- FDA Warning Letter Status: Verify the company's progress in resolving the March 2025 FDA warning letter and any subsequent regulatory actions.
- Reimbursement Impact: Monitor the impact of the 2028 CMS competitive bidding program on Medicare reimbursement rates and pricing strategies.
- Legal Exposure: Track developments in pending securities and product liability class actions, specifically regarding the G7 device accuracy and manufacturing quality allegations.
- Manufacturing Capacity: Assess the timeline and success of the new manufacturing facility in Athenry, Ireland, to meet demand for G7 and G7 15 Day systems.
- Customer Growth vs. Pricing: Analyze whether customer acquisition rates can offset anticipated pricing headwinds from rebates and competitive bidding.